论文部分内容阅读
目的 :评价氯诺昔康治疗中重度骨转移性癌痛的疗效和耐受性。方法 :晚期肿瘤伴有中重度骨转移癌痛患者 6 0例 ,随机分为氯诺昔康治疗组 4 0例和单一吗啡对照组 2 0例 ,疗程 30d。对 2组患者的临床资料进行统计和分析。结果 :治疗组疼痛完全缓解 13例 ,明显缓解 10例 ,中度缓解 8例 ,轻度缓解 7例 ,无缓解 2例 ;有效率77 5 % ,显效率 5 7 5 %。对照组疼痛完全缓解 1例 ,明显缓解 8例 ,中度缓解为 4例 ,轻度缓解 4例 ,无缓解 3例 ;有效率 6 0 % ,显效率 4 5 %。结论 :氯诺昔康治疗中重度骨转移性癌痛有显著疗效 ,耐受性好 ;联合吗啡治疗骨转移性癌痛可减少吗啡用量 ,减轻吗啡的不良反应 ,提高晚期肿瘤患者的生活质量。
Objective: To evaluate the efficacy and tolerability of lornoxicam in the treatment of moderate-to-severe bone metastatic cancer pain. Methods: Sixty patients with advanced cancer with moderate-severe bone metastatic cancer were randomly divided into l0 cases of lornoxicam-treated group and 20 cases of single-morphine control group. The course of treatment was 30 days. The clinical data of two groups were statistically analyzed. Results: In the treatment group, 13 cases were completely relieved of pain, 10 cases were significantly relieved, 8 were moderately relieved, 7 were mildly relieved, and 2 were not relieved. The effective rate was 77.5% and the effective rate was 57.5%. In the control group, pain relief was completely relieved in 1 case, significant relief in 8 cases, moderate remission in 4 cases, mild remission in 4 cases and no remission in 3 cases. The effective rate was 60% and the effective rate was 45%. CONCLUSION: Lornoxicam is effective in treating moderate-to-severe bone metastatic cancer pain and is well tolerated. Combined morphine treatment of bone metastatic cancer pain can reduce the dosage of morphine, reduce the adverse reaction of morphine and improve the quality of life of patients with advanced cancer.